Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
GPR30 and estrogen receptor expression: New insights into hormone dependence of inflammatory breast cancer
Breast Cancer Research and Treatment, Volume 123, No. 1, Year 2010
Notification
URL copied to clipboard!
Description
GPR30 is a novel G protein-coupled estrogen receptor (ER) associated with metastases in breast cancer (BC) and poor survival in endometrial and ovarian tumors. The association of GPR30 expression with inflammatory breast cancer (IBC), an aggressive and commonly hormone-independent form of BC, has not been studied. GPR30, ER, progesterone receptor (PR), epidermal growth factor receptor (EGFR), and HER-2 expression were assessed by immunohistochemistry (and FISH for HER-2) in 88 primary IBCs. GPR30 expression was correlated with patient overall survival (OS), disease-free survival (DFS), pathologic variables, and other biomarkers. GPR30 expression was found in 69% of IBC cases. ER, PR, HER-2, and EGFR were found in 43, 35, 39, and 34% of IBC cases, respectively. GPR30 expression correlated inversely with ER expression (P = 0.02). Co-expression of ER and GPR30 was found in 24% of IBC samples; 19% expressed only ER and 46% expressed only GPR30. Univariate analysis showed no association between GPR30 expression and OS or DFS. However, co-expression of ER and GPR30 was associated with improved OS (P < 0.03) and marginally with DFS (P < 0.06); the absence of both ER and GPR30 was associated with worse OS and DFS (P = 0.03 for both). Multivariate analysis identified ER as an independent prognostic factor of OS (P = 0.008) and DFS (P = 0.02). The majority of IBC tumors are GPR30-positive, suggesting that estrogen signaling may be active in ER-negative IBC patients. These findings suggest potential new therapeutic targets for IBC such as novel endocrine agents or direct modulation of GPR30. © 2009 Springer Science+Business Media, LLC.
Authors & Co-Authors
Arias-Pulido, Hugo
United States, Albuquerque
Unm Comprehensive Cancer Center
Royce, Melanie E.
United States, Albuquerque
Unm Comprehensive Cancer Center
Gong, Yun
United States, Houston
The University of Texas Md Anderson Cancer Center
Joste, Nancy Elaine
United States, Albuquerque
Unm Comprehensive Cancer Center
Lomo, Lesley
United States, Albuquerque
Unm Comprehensive Cancer Center
Lee, Sang Joon
United States, Albuquerque
Unm Comprehensive Cancer Center
Chaher, Nabila
Algeria, Algiers
Centre Pierre et Marie Curie
Verschraegen, Claire F.
United States, Albuquerque
Unm Comprehensive Cancer Center
Lara, J.
United States, Houston
The University of Texas Md Anderson Cancer Center
Prossnitz, Eric R.
United States, Albuquerque
Unm Comprehensive Cancer Center
Cristofanilli, Massimo A.
United States, Houston
The University of Texas Md Anderson Cancer Center
Statistics
Citations: 77
Authors: 11
Affiliations: 3
Identifiers
Doi:
10.1007/s10549-009-0631-7
ISSN:
01676806
e-ISSN:
15737217
Research Areas
Cancer
Health System And Policy